You are here: Home » Reuters » News
Business Standard

Merck, Bristol-Myers immunotherapies impress in key lung cancer trials


By Bill Berkrot(Reuters) - Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone in newly-diagnosed patients with advanced non-small cell lung cancer in a highly-anticipated study that appears to cement the company's lead in the most lucrative oncology market.While magnitude of the survival benefit in the late-stage study was not yet known, the Keytruda combination cut the risk of death by 51 percent compared with chemotherapy and significantly delayed disease worsening, according to data presented on Monday."This study showed ...

This article is no longer available in our repository.

There could be multiple reasons for this.

First Published: Mon, April 16 2018. 19:16 IST